Tech Blogs

Connected Care News | 20 November 2026

Connected Care News | 20 November 2026

A new option for agitation at home: what the Igalmi approval means for families

If you have sat with someone you love through an episode of rising agitation (the pacing, the raised voice, the fear on both sides) and wondered whether the ER was your only choice, this news is for you.

On November 16, the FDA approved Igalmi (dexmedetomidine) sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. It is a thin film placed under the tongue or behind the lower lip. Before this approval, it could only be given under a healthcare provider’s supervision. It is now the first FDA-approved treatment patients can take themselves at home during an agitation episode.

Why it matters: between 25% and 40% of people with these diagnoses may experience agitation, and about 21% of acute episodes end in an emergency department visit or hospitalization. The approval rests on the SERENITY At-Home trial, a 12-week phase 3 study, in which participants on the drug treated 1,160 agitation episodes.

What families can do with this news

  • Bring it to the next appointment. Ask the prescriber whether Igalmi is a fit for your loved one, and what the plan is if it doesn’t help.
  • Ask what your role is. The approval is for self-administration. Ask how you can help your loved one notice the early signs, and which side effects you should watch for.
  • Write it into the crisis plan. A medication on the shelf only helps if everyone knows when to use it and when to call for more help.
  • It doesn’t replace emergency help. If anyone is in danger, call or text 988 or call 911.

This is a medication, not a gadget, but it fits the question we keep asking in Connected Care: what helps families in the stretch between the appointment and the crisis?

Avatar therapy for voices: it helps, and now we know what it costs

Last week I wrote about avatar therapy for schizophrenia, in which a person faces a virtual-reality version of the voice they hear and practices talking back. A new study answers the question that usually comes next: is it worth paying for?

Researchers in Hungary, Poland, and Spain ran an economic evaluation alongside a clinical trial of adults whose voices had not responded to standard treatment. That group is large: roughly 25% to 30% of people with these symptoms don’t respond to conventional treatment. Each participant spent 12 weeks on a waiting list with usual care, then 12 weeks in avatar therapy. Sixty-two people made it into the main analysis (trial NCT06505564).

What they found, from the published paper in Health Economics Review:

  • On the waiting list, little changed. During therapy, voice symptoms dropped meaningfully, with the biggest change in how distressing the voices felt.
  • People believed their voices less. Participants were less convinced that the voices were all-powerful or out to harm them.
  • The extra cost was modest. It came to about €316 per person for the health system, and €267 once work productivity was counted.
  • It fell within what European health systems usually accept as good value.

The researchers are clear that this is early evidence. The study was small and short, and it didn’t randomize people. Larger trials are still needed.

For families, my takeaway is this: when a treatment shows it can work and that it’s affordable, the next question is who will offer it and who will pay. That’s a question we can start asking our care teams and our insurers now.

For more, sign up for the Connected Care newsletter at ResourcesforSMI.

Post Tags :
Share This :

Leave a Reply

Your email address will not be published. Required fields are marked *